Watson To Acquire Schein: Generic Business Projected At $800 Mil. In 2001
Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.
Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.